Please assess the completion status of the following clinical trial:

Trial Title: Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed~* Inadequate response to NSAID and/or non-biologic DMARD~* Minimum of 3 swollen and 3 tender joints~* Active psoriatic skin lesions over minimum 3% body surface area~* high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL~Exclusion Criteria:~* Previously received or currently receiving concomitant biologic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PBO: Placebo matching BMS-945429 (Type: PLACEBO_COMPARATOR): None
- BMS-945429 (25mg) (Type: EXPERIMENTAL): None
- BMS-945429 (100mg) (Type: EXPERIMENTAL): None
- BMS-945429 (200mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).